Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials.
Efficacy of Chinese traditional patent medicines for heart failure with preserved ejection fraction: a Bayesian network meta-analysis of 64 randomized controlled trials.
复制标题
中国传统专利药物对心力衰竭的疗效，并保留了射血分数：64个随机对照试验的贝叶斯网络荟萃分析。
DOI：
10.3389/fcvm.2023.1255940
复制
发表时间：
2023
影响因子：
3.6
通讯作者：
Zhao, Qifei
中科院分区：
文献类型：
--
作者：
Guo, Hongxin;Zhu, Mingjun;Yu, Rui;Li, Xingyuan;Zhao, Qifei
关键词：
射血分数保留性心力衰竭（HFpEF）与大量发病率和死亡率相关，现代医学对HFpEF的治疗效果较差。大量证据表明中成药对HFpEF有良好的疗效，但不同中成药治疗HFpEF的优缺点尚不清楚。本研究使用网络荟萃分析（NMA）比较不同CTPM治疗HFpEF的临床疗效。计算机检索自成立至2023年9月的7个中英文数据库：中国知网（CNKI）、万方、维普、中国生物医学、PubMed、科克伦图书馆、Embase。两名研究人员独立筛选文献，提取数据，并评估纳入研究的质量。使用R（版本4.1.2）中的GeMTC包执行贝叶斯NMA。共纳入64项RCT，涉及6项CTPM和6，238例患者。6种中成药分别为芪荔强心胶囊、芪参益气滴丸、益心舒胶囊、养心石片、麝香保心丸和通心络胶囊。对照组给予西医常规治疗，实验组给予中西医结合治疗。结果表明：CPTMs + CWM均上级CWM单用; SXBXP + CWM改善纽约心脏协会心功能分级效率最好; TXLC + CWM改善舒张早期二尖瓣血流速度与舒张晚期二尖瓣血流速度比值（E/A）最好; QSYQDP + CWM降低N末端B型利钠肽前体最好（NT-proBNP）; QSYQDP + CWM在改善6 min步行试验方面效果最好。在安全性方面，CTPMs + CWM和CWM之间没有显著差异。CTPMs + CWM联合治疗HFpEF较单纯CWM有一定优势，安全性好。芪参益气汤+中西药和三仙补脾汤+中西药可能是治疗HFpEF的最佳中西医结合方案。鉴于本研究的局限性，需要进一步的高质量、多中心、大样本、随机、双盲研究来证实目前的结果。标识符，CRD 42022303938。
Heart failure with preserved ejection fraction (HFpEF) is associated with substantial morbidity and mortality, and modern medicine offers less effective treatment for HFpEF. Much evidence shows that Chinese traditional patent medicines (CTPMs) have good efficacy for HFpEF, but the advantages and disadvantages of different CTPMs for HFpEF are still unclear. This study used network meta-analysis (NMA) to compare clinical efficacies of different CTPMs for HFpEF. Randomized controlled trials (RCTs) of CTPMs for treating HFpEF were searched in seven Chinese and English databases from inception to September 2023: China National Knowledge Infrastructure (CNKI), Wanfang, VIP, China Biology Medicine, PubMed, Cochrane Library, and Embase. Two researchers independently screened the literature, extracted data, and evaluated the quality of the included studies. The GeMTC package in R (version 4.1.2) was used to perform Bayesian NMA. A total of 64 RCTs were included, involving six CTPMs and 6,238 patients. The six CTPMs were Qili Qiangxin capsule (QLQXC), Qishen Yiqi dropping pill (QSYQDP), Yixinshu capsule (YXSC), Yangxinshi tablet (YXST), Shexiang Baoxin Pill (SXBXP), and Tongxinluo capsule (TXLC). Conventional Western medicine (CWM) treatment was given to the control group, and CWM treatment combined with CTPM treatment was given to the experimental group. The results indicated that CPTMs + CWM were all superior to CWM alone; SXBXP + CWM had the best efficacies in improving the New York Heart Association cardiac functional classification efficiency; TXLC + CWM was best at improving the ratio of early diastolic mitral inflow velocity to late diastolic mitral inflow velocity (E/A); QSYQDP + CWM was best at reducing N-terminal pro-B type natriuretic peptide (NT-proBNP); and QSYQDP + CWM was best at improving the 6-min walking test. In terms of safety, there was no significant difference between CTPMs + CWM and CWM. Compared with CWM alone, CTPMs + CWM combinations have certain advantages and good safety in the treatment of HFpEF. QSYQDP + CWM and SXBXP + CWM may be the potential optimal integrative medicine-based treatments for HFpEF. Given the limitations of this study, further high-quality, multicenter, large sample, randomized, and double-blind studies are needed to confirm the current results. identifier, CRD42022303938.
登录
查看更多内容
影响因子：
5.6
作者：
通讯作者：
--
影响因子：
2.9
作者：
Guo Hong-xin;Wang Jian-ru;Zhu Ming-jun
通讯作者：
Zhu Ming-jun
DOI：
10.3760/cma.j.issn.0253-3758.2018.10.004
发表时间：
2018-10-24
期刊：
Zhonghua xin xue guan bing za zhi
影响因子：
--
作者：
通讯作者：
--
影响因子：
37.8
作者：
Heidenreich, Paul A.;Bozkurt, Biykem;Yancy, Clyde W.
通讯作者：
Yancy, Clyde W.
影响因子：
2.9
作者：
Liu, Si-pei;Zhou, Jian-guan;Jin, Yan;Guo, Yan;Zhou, Shi-wei;Lin, Mei-lan;Zhang, Jun;Wang, Xiao-nv;Guan, Xia-fei;Wang, Lei
通讯作者：
Wang, Lei